Episurf Medical AB (LTS:0QUT) Ending Cash Position: kr30.30 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Episurf Medical AB Ending Cash Position?

Episurf Medical AB LTS:0QUT +2.67% Ending Cash Position is kr30.30 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Episurf Medical AB's Ending Cash Position for the quarter that ended in Jun. 2026 was kr30.30 Mil.

Episurf Medical AB's quarterly Ending Cash Position increased from Dec. 2025 (kr7.10 Mil) to Mar. 2026 (kr12.20 Mil) and increased from Mar. 2026 (kr12.20 Mil) to Jun. 2026 (kr30.30 Mil).

Episurf Medical AB's annual Ending Cash Position declined from Dec. 2023 (kr57.90 Mil) to Dec. 2024 (kr50.50 Mil) and declined from Dec. 2024 (kr50.50 Mil) to Dec. 2025 (kr7.10 Mil).

Episurf Medical AB Ending Cash Position Related Terms

Episurf Medical AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Episurf Medical AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Episurf Medical AB Ending Cash Position Chart

Episurf Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.90 155.30 57.90 50.50 7.10

Episurf Medical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 21.70 7.10 12.20 30.30

Episurf Medical AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Episurf Medical AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=50.5+-43.4
=7.10

Episurf Medical AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=11.7+18.6
=30.30

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr30.30 Mil mean?
Episurf Medical AB (LTS:0QUT) has a Ending Cash Position of kr30.30 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Episurf Medical AB and its competitors.
Is Episurf Medical AB's Ending Cash Position too high?
Episurf Medical AB's current Ending Cash Position is kr30.30 Mil.
How does Episurf Medical AB's Ending Cash Position compare to ABT and SYK?
Episurf Medical AB's Ending Cash Position of kr30.30 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Episurf Medical AB and its competitors. Episurf Medical AB's current Ending Cash Position is kr30.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (LTS:0QUT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.08 — trading 54% above its estimated fair value. The current Ending Cash Position is kr30.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Episurf Medical AB (LTS:0QUT), the current Ending Cash Position is kr30.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Episurf Medical AB Business Description

Other Exchanges EPIS B:Sweden16E:Germany
Address Karlavagen 60, Stockholm, SWE, 114 49
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.